Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Eli Lilly Resolves Pending Patent Litigation for Best-Selling Cialis

XTALKS VITALS NEWS

Court

The pending patent litigation surrounded a unit dose patent for Cialis which was set to expire on April 26, 2020.

Share this!

July 14, 2017 | by Sarah Hand, M.Sc.

After going head-to-head with generic drugmakers in the US District Court for the Eastern District of Virginia, Eli Lilly has reached an agreement with the competitors regarding the impending patent expiration of its best-selling erectile dysfunction drug, Cialis (tadalafil). The pending patent litigation surrounded a unit dose patent for Cialis which was set to expire on April 26, 2020.

As part of the settlement agreement, Lilly’s market exclusivity for Cialis is expected to end on September 27, 2018, at the earliest. The agreement will delay the patent cliff for Lilly, but not for long.

“The unit dose patent for Cialis is valid and infringed by companies seeking to market a generic version of Cialis,” said Michael J. Harrington, senior vice president and general counsel for Lilly. “This is a royalty-bearing license agreement that provides us with more certainty regarding our US exclusivity. Protection of intellectual property and the assurance of market exclusivity are extremely important to Lilly as we work to support the development of the next generation of innovative medicines.”



Tadalafil, the active ingredient in Cialis, is also marketed at Adcirca which is indicated for the treatment of pulmonary arterial hypertension. Lilly expects the patent for this indication to expire as early as November 21, 2017, however that date could be extended to May 21, 2018 if the FDA approves the company’s application for exclusivity in the pediatric population.

In 2016, Cialis brought in $2.47 billion in sales for Lilly, representing over 10 percent of the company’s total annual revenue. The company is betting on newly-launched drugs – including type 2 diabetes drug Trulicity (dulaglutide), and Taltz (ixekizumab), a treatment for plaque psoriasis – to help them maintain annual growth through the loss of exclusivity for Cialis.

In 2014, reports surfaced that Lilly was looking into launching an over-the-counter (OTC) version of Cialis to help improve access to the drug and give the company a way to boost sales before patent expiry. Earlier this year, the British Medicines and Healthcare Products Regulatory Agency (MHRA) announced that they were considering making rival erectile dysfunction drug Viagra, available OTC in the UK.


Keywords:  Drug Patent, Generic, Market Exclusivity


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.